Stocks · News reference

Compass Therapeutics shares are trading higher after Piper Sandler raised its price target on the stock from $4 to $6.

Aug 7, 2026, 6:28 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 7, 2026, 4:58 PMBenzinga Newsdesk
Piper Sandler Maintains Overweight on Compass Therapeutics, Raises Price Target to $6
Piper Sandler analyst Biren Amin maintains Compass Therapeutics (NASDAQ:CMPX) with a Overweight and raises the price target from $4 to $6.
Read original at benzinga
CMPX
BenzingaAug 6, 2026, 11:56 AMBenzinga Newsdesk
Compass Therapeutics Q2 EPS $(0.13) Misses $(0.11) Estimate
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 7.14 percent increase over losses of $(0.14) per share
Read original at benzinga
CMPX
SEC EDGARAug 6, 2026, 11:30 AMSEC EDGAR
8-K filing — Compass Therapeutics, Inc. (CMPX)
Filed: 2026-08-06 AccNo: 0001171843-26-005292 Size: 266 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar
CMPX